Home Therapeutic Areas Anti-Neoplastic
Product information is intended for healthcare professionals. Please refer to the approved prescribing information for full details of indications, dosage and safety.
Imalar® (Imatinib) 100 mg & 400 mg film-coated tablets are indicated for the treatment of CML, Ph+ ALL, MDS/MPD, and HES/CEL.
Azacitidine SPC® (Azacitidine) 100 mg powder for solution for injection is indicated for the treatment of MDS and AML in adults ineligible for stem cell transplantation.
Ensutine® (Bendamustine Hydrochloride) 180 mg/4 mL concentrate for solution for infusion is indicated for the treatment of Chronic Lymphocytic Leukaemia (CLL).
CEKEA® (Hydroxyurea [Hydroxycarbamide]) is indicated for the treatment of chronic myeloid leukemia (CML) and cervical cancer. Available in 200 mg and 500 mg capsules.
Otrasa® (Dasatinib) is indicated for the treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults and pediatric patients. Available as 50 mg, 70 mg, and 100 mg film-coated tablets.
Carfilzomib SPC® (Carfilzomib) is indicated for the treatment of multiple myeloma in adults who have received at least one prior therapy. Available as a 60 mg vial for injection.
Bortezomib SPC® (Bortezomib) is indicated for the treatment of multiple myeloma (MM). Available as a 3.5 mg powder for solution for injection.
Pomalidomide SPC® (Pomalidomide) is indicated for the treatment of relapsed or refractory multiple myeloma in adults, in combination with other therapeutic agents. Available as 1 mg, 2 mg, 3 mg, and 4 mg capsules.
Lenalidomide SPC® (Lenalidomide) is indicated for the treatment of multiple myeloma (MM), myelodysplastic syndrome (MDS), mantle cell lymphoma (MCL), and follicular lymphoma (FL) in adults. Available as 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg capsules.
Deroxi Liposomal® (Doxorubicin Hydrochloride) is indicated for the treatment of breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma. Available as a 2 mg/mL concentrate for solution for infusion.
Fulvestrant SPC® (Fulvestrant) is indicated for the treatment of hormone receptor-positive advanced or metastatic breast cancer in adults, either alone or in combination with other therapies. Available as a 250 mg/5 mL pre-filled syringe.
Docetaxel SPC® (Docetaxel) is indicated for the treatment of early and advanced breast cancer. Available as an 80 mg/4 mL vial for injection.
Capecitabine SPC® (Capecitabine) is indicated for the treatment of colon, rectal, gastric, and breast cancers. Available as 150 mg and 500 mg film-coated tablets.
Erlotinib SPC® (Erlotinib Hydrochloride) is indicated for the treatment of advanced EGFR mutation-positive non-small cell lung cancer (NSCLC) and metastatic pancreatic cancer. Available as 25 mg, 100 mg, and 150 mg film-coated tablets.
Pemetrexed SPC® (Pemetrexed) is indicated for the treatment of malignant pleural mesothelioma and advanced non-small cell lung cancer (NSCLC). Available as a 500 mg concentrate for solution for infusion.
Cabazitaxel SPC® (Cabazitaxel) is indicated for the treatment of advanced prostate cancer following prior chemotherapy. Available as a 60 mg/1.5 mL vial for injection.
Abiraterone Acetate SPC® (Abiraterone Acetate) is indicated for the treatment of metastatic prostate cancer in adult men. Available as 250 mg and 500 mg film-coated tablets.
